Terms: = Thyroid cancer AND PR, PGR, progesterone receptor AND Treatment
161 results:
1. pgr-KITLG signaling drives a tumor-mast cell regulatory feedback to modulate apoptosis of breast cancer cells.
Yang Z; Chen H; Yin S; Mo H; Chai F; Luo P; Li Y; Ma L; Yi Z; Sun Y; Chen Y; Wu J; Wang W; Yin T; Zhu J; Shi C; Zhang F
Cancer Lett; 2024 May; 589():216795. PubMed ID: 38556106
[TBL] [Abstract] [Full Text] [Related]
2. Adjuvant chemotherapy and survival in males aged 70 years or older with breast cancer: a population-based retrospective study.
Yu Y; Huang K; Liu Y; Chen R; Yu X; Song C
BMC Geriatr; 2024 Mar; 24(1):282. PubMed ID: 38528444
[TBL] [Abstract] [Full Text] [Related]
3. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast cancer Registry.
Iwamoto T; Kumamaru H; Niikura N; Sagara Y; Miyashita M; Konishi T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Watanabe C; Kinukawa N; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):185-194. PubMed ID: 38319565
[TBL] [Abstract] [Full Text] [Related]
4. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of pretreatment FDG PET-CT for short-term efficacy of radioactive iodine-125 seed implantation in patients with NSCLC.
Hu T; Shen J; Shao M; Feng X; Lu D; Ding E
Brachytherapy; 2023; 22(6):882-888. PubMed ID: 37758577
[TBL] [Abstract] [Full Text] [Related]
6. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
7. Seroprevalence of Toxoplasma gondii infection among patients of a tertiary hospital in Guangzhou, Guangdong province, PR China.
Guan YB; Sun XX; Chen SL; Zhu XT; Zeng ZH; Lu HW; Feng HM; Guo Y; Jiang WG; Xiong K; Yang XR; Nam HW; Yang ZS
PLoS One; 2023; 18(7):e0286430. PubMed ID: 37428723
[TBL] [Abstract] [Full Text] [Related]
8. Intrathoracic synovial sarcoma with BRAF V600E mutation.
Russo I; Barresi S; Di Paolo PL; Di Ruscio V; Del Baldo G; Serra A; Vallese S; Miele E; Mastronuzzi A; Alaggio R; Ferrari A; Milano GM
Oncotarget; 2023 Jul; 14():703-708. PubMed ID: 37417899
[TBL] [Abstract] [Full Text] [Related]
9. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract] [Full Text] [Related]
10. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract] [Full Text] [Related]
11. Primary Ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.
Chen X; Liu HL; Wang JS; Zhao FH
Chin Med Sci J; 2023 Jun; 38(2):130-137. PubMed ID: 37286512
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma.
Zheng X; Wang J; Ye T; Tang W; Pan X; Wang S; Liu J
Endocrine; 2023 Sep; 81(3):540-546. PubMed ID: 37219702
[TBL] [Abstract] [Full Text] [Related]
13. The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours.
Resteghini C; Castelnuovo P; Nicolai P; Orlandi E; Bossi P; Vischioni B; Schreiber A; Gambazza S; Iacovelli NA; Battaglia P; Guzzo M; Turri-Zanoni M; Mattavelli D; Facchinetti N; Calareso G; Ravanelli M; Facco C; Tartaro T; Licitra L
Eur J Cancer; 2023 Jul; 187():185-194. PubMed ID: 37164774
[TBL] [Abstract] [Full Text] [Related]
14. Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast cancers and thyroid Disease.
Li J; Liu Y; Jin J; Shi Q; Ji Y; Zhang B; Hu P
Mediators Inflamm; 2023; 2023():3133554. PubMed ID: 37152372
[TBL] [Abstract] [Full Text] [Related]
15. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
[TBL] [Abstract] [Full Text] [Related]
16. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated thyroid cancer.
Leboulleux S; Do Cao C; Zerdoud S; Attard M; Bournaud C; Lacroix L; Benisvy D; Taïeb D; Bardet S; Terroir-Cassou-Mounat M; Anizan N; Bouvier-Morel E; Lamartina L; Lion G; Betrian S; Sajous C; Schiazza A; Garcia ME; Ciappuccini R; Schlumberger M; Al Ghuzlan A; Godbert Y; Borget I
Clin Cancer Res; 2023 Jul; 29(13):2401-2409. PubMed ID: 37074727
[TBL] [Abstract] [Full Text] [Related]
17. Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
Fu R; Zou Y; Wu Z; Jin P; Cheng J; Bai H; Huang M; Huan X; Yuan H
Sci Rep; 2023 Apr; 13(1):5956. PubMed ID: 37046020
[TBL] [Abstract] [Full Text] [Related]
18. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated thyroid Carcinoma and Medullary thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract] [Full Text] [Related]
19. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
[TBL] [Abstract] [Full Text] [Related]
[Next]
